DNA Replication as a Target of Novel Antibacterial Drugs

Information

  • Research Project
  • 6492200
  • ApplicationId
    6492200
  • Core Project Number
    R43GM065743
  • Full Project Number
    1R43GM065743-01
  • Serial Number
    65743
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2001 - 23 years ago
  • Project End Date
    3/14/2002 - 22 years ago
  • Program Officer Name
    WOLFE, PAUL B.
  • Budget Start Date
    9/15/2001 - 23 years ago
  • Budget End Date
    3/14/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/3/2001 - 23 years ago
Organizations

DNA Replication as a Target of Novel Antibacterial Drugs

DESCRIPTION (provided by applicant): Drug resistance among bacterial pathogens is becoming a serious health problem worldwide. Since the basic mechanism for resistance to many existing antibacterials is already widespread, the health care industry is currently in severe need of novel, mechanistically distinct antibacterials. To date, none of the commercially available antibacterials target any of the components of the replication system in bacteria. Since DNA replication is essential for the propagation of bacteria, such compounds would represent a novel class of antibacterial drugs. The overall aim of this project is to identify a diverse set of small molecules that inhibit targets within a replication system. A fluorescence-based assay will be set up in a high-throughput screening format in which synthesis of DNA is dependent on the coordinated function of 12 protein components of the E. coli replication apparatus. Initial screen will sample a chemical library consisting of approximately 5,000 molecules. For several most active compounds, in vitro potency will be established and targets within the replication system identified. This work will form the basis for an expanded screen of larger compound libraries and lead optimization of promising antibacterial drug candidates within the two-year phase II period. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    REPLIDYNE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LOUISVILLE
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80027
  • Organization District
    UNITED STATES